



STUDY MATTERS

September 29, 2022

Wake NCORP Website: <https://wakencorp.phs.wakehealth.edu/>

Register Now!

You must register as Virtual in order to receive the WebEx invite link to join the Annual Meeting virtually. If you registered as In-Person by mistake, you may contact us at NCORP@wakehealth.edu.

Wake Forest NCORP Research Base Annual Meeting

October 10 – 11, 2022 @ The Marriott Grand Dunes Resort & Spa, Myrtle Beach, SC



Our keynote speaker this year will be Dr. Ray Osarogiagbon from the Baptist Memorial Health Care/Mid South Minority Underserved NCORP.

Please use the **Registration** link below to register for the upcoming 9th Annual Wake Forest NCORP Research Base Meeting, October 10 – 11, 2022 with the Northwest AHEC. You will be asked if you will attend In-Person or Virtual. The link below should take you to the facepage and a gray “Register” button. Once you click on this button, you will be asked to Sign In. If you do not have an account, you will need to create one at this time using the links on this page.

www.nwahec.org/69183

The group rate for **Hotel** reservations is no longer valid; however, rooms are still available- https://www.marriott.com/en-us/hotels/myrgd-marriott-myrtle-beach-resort-and-spa-at-grande-dunes/overview/?scid=cd5470db-cd64-4033-afea-9c893567388c&gclid=Cj0KCQjwmouZBhDSARIsALYcourNBOS3YGxqXPowZyT8q89VvOAKRSaRb48ld6FYIfgwZl6ykcKPobkaAh-EEALw_wcB&gclidsrc=aw.ds

To Be Rescheduled: October 12, 2022 iDAPT Training

Due to trainer conflicts, the iDAPT workshop that had previously been scheduled for October 12th immediately following the Wake Forest NCORP Research Base Annual Meeting will be rescheduled. We apologize for this inconvenience.

Study Matters

Study Matters will not be published the week of the Wake Forest NCORP Research Base Annual Meeting. We will resume publication on Thursday, October 27th.

2022 Landscape Assessment

Data Requests

Investigators who wish to use the data for scholarly products should first seek approval from affiliated Research Base and then submit a request to the Landscape Committee using the following

link: <https://redcap.wakehealth.edu/redcapccc/surveys/?s=P9FEAHJLFAWW44FW>

CCDR/Administrator leads at NCORP M/U and Community Sites will have access to affiliates/sub-affiliates dataset, if consent was provided. To request dataset or summary of results contact NCORP@wakehealth.edu

OPEN CALL FOR COMMITTEE MEMBERS

Action Needed by October 31

The Wake Forest NCORP Research Base is soliciting applications for NCORP Community/ M/U Community Site representatives for the

Cancer Control and Cancer Care Delivery Research (CCDR) Scientific Committees and the Health Equity Core Committee.

Community site representation on all committees is being expanded. Responsibilities for members will include:

- Attend committee meetings (monthly for the scientific committees and quarterly for the Health Equity Core)
- Provide feedback about studies early and throughout the study lifecycle to improve feasibility and alignment of studies with community site priorities and provide feedback on implementation challenges
- Provide scientific/feasibility/equity review of new concepts/protocols
- Oversee active studies, including minority/underserved accrual progress
- Periodically review and make recommendations about committee priorities and activities
- Act as a liaison between NCORP community sites/investigators and the Wake Forest NCORP Research Base

We are looking for committee members who bring diversity with regards to their expertise, service within NCORP (PIs or scientific leaders, CRAs, research nursing, and Administrators), and background and populations engaged. Interested individuals should apply using the REDCap link below. The application will include a brief statement (5-10 sentences) on your prior involvement with the Wake Forest NCORP Research Base, experience with cancer control, cancer care delivery research, and/or health equity research, interest in committee service, and contributions to the diversity of the committee. You will also be asked to upload a CV or biosketch. The initial committee term will be 2 years. **The due date to apply is October 31, 2022.** Selection of committee members will take place in November and committees will begin meetings in January 2023.

Click here to

apply: <https://redcap.wakehealth.edu/redcapccc/surveys/?s=PYEDAF7EFY78J773>

For Funding Opportunities Announcements Relevant to NCORP CCDR, click on this link:

<https://healthcaredelivery.cancer.gov/funding/opportunities.html>

Upcoming Site Calls

If you would like to attend one of these calls, but did not receive an invitation,
please email NCORP@wakehealth.edu

Click the button below the meeting to add it to your Outlook Calendar

****Please note that your calendar may not update automatically if changes are made. Please check these emails and our website for meeting updates.****

You can also join site calls from our [Wake NCORP website](#). Click the call in the
"Upcoming Events" section on the Home page or through the Calendar.

WF1801-RAMIPRIL - A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

October 5, 2022 at 2:00pm EDT. Please update your calendars.

[Click to add this WF1801-RAMIPRIL meeting to your calendar](#)

WF1806-M&M - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer

October 12, 2022 Site Call is **cancelled**. Join us for the WF NCORP Research
Base Annual Meeting on October 10-11th.

WF1901-IMPACTS - Internet-delivered Management of Pain Among Cancer Treatment Survivors

November 9, 2022 at 2:30pm EDT. Please update your calendars.

[Click to add this WF1901-IMPACTS meeting to your calendar](#)

New Wake Forest NCORP Research Base Website


Please visit and register on our new Wake Forest NCORP Research Base website

<https://wakencorp.phs.wakehealth.edu/>

Registering for an account will allow you to:

- Join site calls and other meetings from the Upcoming Events or Calendar sections
- Access study training materials
- View previous study meetings
- Download important study documents including training videos, study guides, and neurocognitive CRFs

Once registered, you must update your user profile to sign up for study-specific mailing lists and meeting announcements, indicate your NCORP Community site, add your user roles, and update your GCP for database access.



Email Preferences

NCORP

Other

Subscribe to General Email Updates

☒ General

Studies

☒ WF01213-RELAX
☒ WF01414-NAVIGATOR
☒ WF10217-WAYS
☒ WF1801-RAMIPRIL
☒ WF1802-PCW
☒ WF1803CD-CAREGIVERS
☒ WF1804CD-AH-HA
☒ WF1805CD-HN-STAR
☒ WF1806-M&M
☒ WF1901-IMPACTS
☒ WF20817CD-OASIS
☒ WF30917CD-TELEHEALTH
☒ WF97115-ACUPUNCTURE
☒ WF97116-REMEMBER
☒ WF97415-UPBEAT
☒ WF98213-PREVENT

Roles

☒ CCDR Lead
☒ Investigator
☒ NCORP Administrator
☒ CRA
☒ Data Management
☒ Regulatory
☒ Operations Manager
☒ Quality Control

GCP certificate

Upload new certificate

Choose File

No file chosen

Accepted file types: jpg, png, pdf, jpeg, Max. file size: 2 MB.

Submit

If you have any questions or need assistance with registration please email NCORP@wakehealth.edu

Please email 7NCORP@wakehealth.edu when shipping biospecimen samples to the NCORP Research Base Biospecimens lab (Studies WF-97415, WF-1801, and WF-1901). Include the FEDEX

tracking number in your email so that misplaced samples can be tracked before they spoil. Please ship by "FedEx Priority Overnight" (please change this on the pre-printed shipping label if this is not selected).

Study Updates

WF-1802 - PCW - Influence of Primary Treatment for Prostate Cancer on Work Experience

The Higher Income AA stratum is now full. Please keep this in mind when screening for participants and check the slot reservation report in CTSU-OPEN to see how many slots are available before registering. Try to approach individuals from the lower income white strata that is slowly accruing. The lower income AA strata and higher income white strata are also closed.

WF-1804CD - AH-HA - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors


Thank you to all our sites for your hard work and dedication to this study! We now have **over 500 accruals**! Keep up the great effort and we will reach our accrual goal soon!

WF-1805CD - HN-STAR - Implementation and Effectiveness Trial of HN-STAR

Congratulations on hitting a big milestone- **triple digit accruals!** Thanks to all your hard work in recruiting, we now have **107** patients enrolled in HN-STAR! Keep the momentum going! If your site is interested in joining this study, please email NCORP@wakehealth.edu for more information.

WF-1901 - IMPACTS - Internet-delivered Management of Pain Among Cancer Treatment Survivors

The videos which were presented as part of the bi-monthly site call on September 14, 2022, have been posted to the Wake NCORP website; <https://wakencorp.phs.wakehealth.edu/> . These can be found within the **WF-1901 Study page** under **FAQs / Helpful Guidelines**. Look for *Dr. Christine Rini discusses painTRAINER®* and *Dr. Judith Paice discusses Cancer Pain*. Feel free to use these videos to engage additional champions for this study at your site.



WF-97116 - REMEMBER - A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairments

As we are updating our policies/procedures on CTSU study status, such as *close to enrollment*, *complete* and *FDAAA/IRB complete*, we want to clarify the status for WF-97116 the Remember study.

We recently stated that your sites could close this study with your local IRB and/or CIRB, as it was assigned the status of *complete* (*Note Special Broadcast dated 08/01/22 and Study Matters dated 08/04/22*). However, we ask that you do not submit a request for closure at this time, as the data is still being analyzed and audited during this *complete* status.

Going forward in our updated policies/procedures, we will not allow sites to close studies with their local IRB and/or CIRB until we have notified you that the study has been assigned the CTSU status of *FDAAA/IRB completed*.

If you have already closed this at your site with your local IRB and/or CIRB prior to today, we ask that you send us an email to NCORP@wakehealth.edu with your approved IRB closure memo to let us know.

We appreciate your cooperation and continued support to our studies!

WF-97415 - UPBEAT - Understanding and Predicting Breast Cancer Events after Treatment

UPCOMING PRESENTATIONS

UPBEAT WF97415	Longitudinal assessment of racial differences in exercise capacity after breast cancer treatment: WF-97415	Reding, KW, O'Connell, NS, Szewczyk, W, Cheng, RK, Nguyen, J, Ladd, A, Jordan, J, Lucas, A, Shepherd, V, Ge, Y, Salloum, F, Kim, Y, Lesnefsky, E, Franco, RL, Melendez, G, Sutton, A, D'Agostino Jr, R, Weaver, KE, Lesser, GJ, Hundley, WG	American Heart Association	Poster Session for in-person presentation	November 5–7 2022	Chicago, IL
UPBEAT WF97415	Hypertension Severity Impacts Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (UPBEAT WF-97415)	Garg, R, O'Connell, N, Lesser, GJ, Jordan, JH, Sutton, A, Bottinor, W, Ladd, A, D'Agostino Jr., R, Hundley, WG, the UPBEAT Study Team	American Heart Association	Poster Session for in-person presentation	November 5–7 2022	Chicago, IL

WF-98213 - PREVENT - Preventing Anthracycline Cardiovascular Toxicity with Statins

RECENT PUBLICATION

Hundley WG, D'Agostino R, Crotts T, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evidence. 2022:EVIDoa2200097.



ORIGINAL ARTICLE

Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment

W. Gregory Hundley, M.D.¹, Ralph D'Agostino, Jr., Ph.D.², Teresa Crotts, B.S.³, Karen Craver, M.T.⁴, Mary Helen Hackney, M.D.⁵, Jennifer H. Jordan, Ph.D.^{1,6}, Bonnie Ky, M.D.⁷, Lynne I. Wagner, Ph.D.⁴, David M. Herrington, M.D., M.H.S.³, Joseph Yeboah, M.D.³, ...

[Show More](#) 

Article

Figures/Media

23 References 1 Citing Article

Abstract

BACKGROUND

Statins taken for cardiovascular indications by patients with breast cancer and lymphoma during doxorubicin treatment may attenuate left ventricular ejection fraction (LVEF) decline, but the effect of statins on LVEF among patients with no cardiovascular indications is unknown.

 Tweet

Published August 18, 2022
NEJM Evid 2022; 1 (9)
DOI: <https://doi.org/10.1056/EVIDoa2200097>

[Issue](#) >

ADVERTISEMENT

UPCOMING PRESENTATION

PREVENT WF98213	Examining the association between socioeconomic factors and left ventricular ejection fraction declines in breast cancer and lymphoma survivors receiving doxorubicin: WF-98213	Sutton, AL, O'Connell, NS, Lucas3, AR, Franco, RL, Reding, KW, Kim, Y, Cheng, R, Sheppard, VB, Weaver, KE, Lesser, GJ, Hundley, WG	American Heart Association	Moderated Digital Poster Session for in-person presentation	November 5–7 2022	Chicago, IL
--------------------	---	--	----------------------------	---	-------------------	-------------

Accruals as of September 28, 2022

Open Studies	Name	Enrolled (Patients)	Target (Patients)	Enrolled (Non- Patients)	Target (Non- Patients)
WF-1801	RAMIPRIL	59	75		
WF-1802	PCW	228	255		
WF-1806	M&M	103	300		
WF-1901	IMPACTS	60	456	0	40
WF-1804CD	AH-HA	503	600	24	40
WF-1805CD	HN STAR	107	350	73	140

Copyright © 2022 Wake Forest NCORP Research Base, All rights reserved.

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

